Ischemic preconditioning (IPC) protects brain against ischemic injury by activating specific mechanisms. Our goal was to determine if the inducible heme oxygenase 1 (HO1) is required for such protection. IPC before transient or permanent ischemia reduced cortical infarct volumes by 57.4% and 33.9%, respectively at 48 h in wildtype adult mice. Interestingly, IPC failed to protect the HO1 gene deleted mice against permanent ischemic brain injury. IPC also resulted in a significant increase in HO1 protein levels in the brain and correlated with reduced neurological deficits after permanent and transient brain ischemia. Our study demonstrates that neuroprotective effects of IPC are at least partially mediated via HO1. Elucidating the physiological/cellular role by which HO1 is protective against brain ischemia may aid the development of selective drugs to treat stroke and its associated neurological disorders.
Introduction
Endogenous protective mechanisms against various injuries have developed throughout evolution in living organisms. If such an injury is tolerable, it triggers cellular responses that precondition the body against more severe stimuli. Preconditioning stimuli are diverse in nature and, therefore, can activate various pathways, altered gene translations, and synthesis of proteins, resulting in a stronger phenotype. Ischemic preconditioning (IPC) is a phenomenon in which brief ischemic episodes result in resistance of an organ to later severe ischemic insult(s). In clinical practice, brief ischemic episodes are known as transient ischemic attacks (TIAs) and have been studied for over two decades (Murry et al., 1986; Wegener et al., 2004) . In human brain, TIAs induce tolerance by raising the threshold of tissue vulnerability (Wegener et al., 2004) , a response that is critical for neuroprotection and its underlying molecular mechanisms.
Despite promising results obtained from animal studies and an abundance of experimental neuroprotective compounds, clinical practice still lacks effective methods of stroke therapy. Investigating the underlying mechanisms activated by TIAs, could lead to novel targets for treating or preventing stroke.
Studies of IPC have revealed that tolerance induced in the brain can be early (minutes to hours) or late (hours to days) and that various protective molecular pathways are activated at different time points after IPC (Steiger and Hanggi, 2007) . In particular, expression of the heat shock protein heme oxygenase 1 (HO1) is activated 12 to 24 h after IPC and remains up-regulated for up to 7 days in newborn rat brains (Bergeron et al., 1997) . HO1 is an inducible enzyme that degrades the heme molecule to biliverdin, carbon monoxide (CO), and iron; its expression and activity can be increased by various preconditioning stimuli in the brain and in the whole body. Many investigators have suggested HO1 to be potentially responsible for preconditioning-induced protection in vivo and in vitro. For example, HO1 was reported to be involved in long-term tolerance after hypoxic preconditioning in the retina of mice (Zhu et al., 2007) . Also, cardioprotection in diabetic rats provided by pharmacologic preconditioning was found to be at least partially mediated by HO1 (Thirunavukkarasu et al., 2007) . Similarly, HO1 plays a role in the protection of cultured spinal neurons exposed to hyperbaric preconditioning (Li et al., 2007) . HO1 up-regulation after lipopolysacharide preconditioning was shown to protect intestinal and lung tissue (Tamion et al., 2001) ; and myocardial cells induce HO1 expression after ischemic preconditioning, resulting in protection against apoptotic-like cell death and oxidative stress (Jancso et al., 2007) 
